CRISPR-Cas9–Based Genomic Engineering in Keratinocytes: From Technology to Application

Jos P.H. Smits1, Luca D. Meesters1, Berber G.W. Maste1, Huiqing Zhou2,3, Patrick L.J.M. Zeeuwen1 and Ellen H. van den Bogaard1

CRISPR-Cas9 is the most straightforward genome-editing tool to date. However, its implementation across disciplines is hampered by variable genome-editing efficiencies, reduced cell viability, and low success rates in obtaining clonal cell lines. This review aims to recognize all CRISPR-Cas9–related work within the experimental dermatology field to identify key factors for successful strategies in the different keratinocyte (KC) cell sources available. On the basis of these findings, we conclude that most groups use immortalized KCs for generating knockout KCs. Our critical considerations for future studies using CRISPR-Cas9, both for fundamental and clinical applications, may guide implementation strategies of CRISPR-Cas9 technologies in the (experimental) dermatology field.

JID Innovations (2022);2:100082 doi:10.1016/j.xjidi.2021.100082

Introduction to CRISPR-Cas9 as a genomic editing tool
CRISPRs were known in the bacterial genome as hypervariable loci typically consisting of direct repeats, separated by sections of variable sequences called spacers, in the proximity of CRISPR-Cas genes. The mechanism of the CRISPR-Cas system to specifically target DNA for genome editing was utilized successfully for the first time in mammalian cells almost a decade ago (Cong et al., 2013; Jinek et al., 2012; Mali et al., 2013), and the functions as described extensively (Doudna and Charpentier, 2014) and schematically visualized in Figure 1a. Many bacterial species have variants of CRISPR and Cas loci, with the most extensively investigated variant as a genome-editing tool being the CRISPR-Cas9 system (Makarova et al., 2011).

CRISPR-Cas9–mediated genome editing requires a Cas9–guide RNA (gRNA) complex containing Cas9, CRISPR RNA (crRNA), and trans-activating CRISPR RNA (tracrRNA) (see Box 1: CRISPR Terminology). The complex can be introduced to target cells by various methods, as reviewed before (Lino et al., 2018; Shi et al., 2021). By the guidance of crRNA, the complex binds to complement DNA accompanied by a flanking protospacer adjacent motif 5′-NGG-3′ for Streptococcus pyogenes Cas9 (Chylinski et al., 2013). The Cas9–gRNA complex induces a double-stranded break at the target site (Deltcheva et al., 2011; Shah et al., 2013), which can be repaired by the target cell through either nonhomologous end joining (NHEJ) (Hefferin and Tomkinson, 2005) or homology-directed repair (HDR) (Liang et al., 1998). In NHEJ, the broken DNA strands are religated, either directly or after random nucleotide insertions or deletions (Takata et al., 1998). Often, this leads to frameshift mutations and premature stop codons, and therefore, this mechanism is readily used to knock out protein expression of interest. In HDR, the double-stranded breaks are repaired with the use of a sister chromatid as a homologous template strand. By multiple crossovers, DNA synthesis, and ligation, the damaged strand can be precisely repaired (Takata et al., 1998). Instead of a sister chromatid as template strand, an exogenous DNA template harboring the desired mutation or gene cassette can be introduced as single-strand or double-strand DNA, with homologous arms on the outside (Chen et al., 2011; Radecke et al., 2010; Rouet et al., 1994).

Over the years, an increasing number of studies in the field of experimental dermatology harnessed the CRISPR-Cas9 toolbox, although current numbers are limited but increasing over the past 5 years (Figure 1b and c and Table 1). This review aims to recognize all the CRISPR-Cas9 work performed in human epidermal keratinocytes (KC)s to identify the best practices and key determinants for successful strategies in different human KC cell sources available, accompanied by critical considerations for future studies using CRISPR-Cas9, both for a fundamental and clinical application.

Delivery of the CRISPR-Cas9 machinery into KC
Cationic vectors, lentiviral vectors, or adenoviral vectors are mostly utilized for transducing the expression of Cas9 and a specific gRNA. Lentiviral vectors especially designed for this purpose, such as lentiCRISPR v2 deposited by Feng Zhang’s laboratory (Sanjana et al., 2014), are readily available...
Figure 1. CRISPR-Cas9–initiated genomic repair in human keratinocytes. (a) Schematic overview of CRISPR-Cas9 mechanism (created with BioRender.com). (b, c) Graphical representation of publications using CRISPR-Cas9 in human keratinocytes, split by cell source, experimental goal, carrier system applied, and selection (marker) deployed. iPSC, induced pluripotent stem cell; PAM, protospacer adjacent motif; RNP, ribonucleoprotein; sgRNA, single-guide RNA.
through Addgene (Watertown, MA) (plasmid #52961) and are easily amendable to encode the gRNA sequence(s) of interest. Lentiviral infection is often very efficient and leads to random incorporation of the encoded DNA into the infected cell’s genome, causing a permanent transfer—and often also permanent induction—of Cas9 and the encoded gRNA sequence. Consequently, the constitutive expression of Cas9 and gRNA increases the risk of off-target cleavage of DNA, potentially leading to unforeseen genomic changes. In addition, lentiviral delivery can result in unwanted gene rearrangements and transgene silencing (Lino et al., 2018). The use of adenovirus over lentiviruses is preferred, as adenoviruses do not integrate easily into the genome (Stephen et al., 2010). Both lentivirus and adenovirus can induce strong immunogenic responses (Navak and Herzog, 2010; Zaiß and Muruve, 2008), complicating their suitability for in vivo therapeutic use. Therefore, adeno-associated virus (AAV) particles, which show limited immunogenicity compared with adenovirus vectors (Zaiß et al., 2002), might be more suitable. Nevertheless, the drawback of AAV is that these particles have a smaller loading capacity than adenoviruses and lentiviruses, which can limit their use with relatively large plasmids encoding such gRNAs and Cas9.

Electroporation or transfection of Cas9 and gRNAs, either as plasmids, mRNA, or ribonucleoprotein (RNP) complexes, is nowadays often used in immortalized KCs (Table 1). These delivery methods are easy to use and can be highly efficient (especially electroporation of RNP complexes), and the transient expression of gRNAs and Cas9 limits the risk for off-target effects.

**Box 1. CRISPR Terminology**

| CRISPR          | Clustered Regularly Interspaced Short Palindromic Repeats |
|-----------------|----------------------------------------------------------|
| Cas9            | CRISPR-associated protein 9                              |
| Cas9n           | Cas9 nickase                                             |
| dCas9           | Deactivated Cas9                                          |
| PAM             | Protospacer adjacent motif                                |
| crRNA           | CRISPR RNA                                               |
| tracrRNA        | Trans-activating CRISPR RNA                               |
| (sg)RNA         | (Single) guide RNA                                        |
| RNP             | Ribonucleoprotein                                         |
| HDR             | Homology-directed repair                                  |
| NHEJ            | Nonhomologous end joining                                 |

**CRISPR-Cas9 in human primary KCs**

To study protein function, biological processes, or disease mechanisms, experimental cell or tissue culture models often include primary epidermal KCs of healthy individuals taken from excess skin that was removed during surgical procedures. Genetic predispositions are key in the pathogenesis of many skin diseases, from the obvious monogenic to complex polygenic and multifactorial diseases. For example, ichthyosis vulgaris (IV) and epidermolysis bullosa (EB) are the results of homozygous (or compound heterozygous) mutations in FLG (for IV) and type VII collagen (COL7) gene COL7A1 and LAMB3 (both for EB) (Floeth and Bruckner-Tuderman, 1999; Ryyynänen et al., 1991; Smith et al., 2006; Thyssen et al., 2013). Through genomic engineering, models for these monogenic skin diseases can be created, allowing to study the contribution of the genetic risk factors in an in vitro setting against nonengineered KCs with an identical genetic background. Potential gene therapy strategies can be developed and validated for use in vitro and eventually in vivo. So far, CRISPR-Cas9 has been used in primary KCs, mainly to knockout or correct genes, as shown in Table 1.

In 2018, a protocol for the generation of knockout human primary KCs was published (Fenini et al., 2018a). To increase the lifetime of human primary cells, they were cocultured with 3T3-J2 fibroblasts as feeder cells in the presence of proliferation-enhancing ROCK inhibitor Y-27632 (Gandham et al., 2013), whereas the CRISPR-Cas9 machinery is delivered through lentiviral transduction of plasmid DNA, including a puromycin resistance cassette. Selection of modified KCs was performed on mitotically inactivated and puromycin-resistant fibroblasts. The modified KCs were still able to differentiate and were able to form three-dimensional (3D) skin equivalents (Fenini et al., 2018b; Grossi et al., 2020). In the studies mentioned earlier, antibiotic resistance was often conferred, allowing for the selection of KCs that were successfully infected. These KCs did not undergo successful genomic editing per se. In other words, the generation of isogenic clonal cell lines that harbor precisely the intended mutations is preferred to using selection procedures that will result in a mixed cell population with unspecified genomic alterations. Indeed, clonal expansion of primary KCs is a challenge given the limited lifespan. Nevertheless, EB-derived patient KCs, grown on feeder fibroblast cells and in the presence of Y-27632, were successfully targeted by CRISPR-Cas9 (Bonařont et al., 2021, 2019). Others circumvented the proliferative limitations by immortalizing the genetically altered primary KCs using a retroviral vector carrying human papillomavirus type 16 (HPV16) genes E6 and E7 before grafting experiments and organotypic 3D cultures for studies on junctional epidermolysis bullosa (JEB) (Benati et al., 2018) or Netherton’s syndrome (Gálvez et al., 2020).

Most research utilizing CRISPR-Cas9 in primary KCs is focused on EB using patient-derived EB KCs, as reviewed recently (Kocher and Koller, 2021). In EB, the connection between the dermis and the epidermis is fragile, leading to severe clinical features such as blistering and subsequent debilitating infections. Using CRISPR-Cas9–induced HDR, the COL7 gene COL7A1 in KCs derived from patients with recessive dystrophic EB (RDEB) (Bonařont et al., 2021; Hainzl et al., 2017; Izmiryan et al., 2018; Kocher et al., 2021) and fibroblasts derived from patients with RDEB (Kocher et al., 2021) can be restored, leading to re-expression of COL7. The COL7-corrected KCs were able to develop into high-quality skin equivalents when transplanted onto immunodeficient mice. Others showed that the use of dual single gRNA (sgRNA)-guided Cas9 nuclease can restore the COL7A1 reading frame and reinstate the expression of COL7 in the KCs derived from patients with RDEB, enabling long-term regeneration of high-quality, properly adhesive skin after grafting onto immunodeficient mice (Bonařont et al., 2019). For JEB, a similar approach was successful: primary KCs carrying the homozygous LAMB3 mutation in exon 14 were immortalized and corrected by HDR through an adenoviral vector carrying Cas9 and gRNA cassettes and a lentiviral...
Table 1. Characteristics of Studies that Utilize CRISPR-Cas9 in Human Keratinocytes

| Cell source          | Publication        | PMID     | Cell Types (All Human)     | Research Goal          | Method of Introduction | Carrier          | Cas9 Version | Repair       | Selection     |
|----------------------|--------------------|----------|----------------------------|------------------------|------------------------|-------------------|---------------|--------------|---------------|
| Primary keratinocytes| Nönske et al., 2016| 26828486 | Adult primary keratinocytes| Protein knockout       | Electroporation         | Plasmid vector     | SpCas9        | NHEJ         | FACS          |
|                      | Yue et al., 2017   | 28777946 | Foreskin primary keratinocytes| Gene activation       | Electroporation         | Plasmid vector     | hCas9         | HDR          | Puromycin     |
|                      | Haínz et al., 2017 | 28800953 | RDEB primary keratinocytes | Gene correction        | Xfect                   | Cationic vector    | SpCas9        | HDR          | Puromycin and blasticidin |
|                      | Kocher et al., 2017| 28888469 | Adult primary keratinocytes| Protein knockout       | Electroporation         | Plasmid vector     | SpCas9        | NHEJ         | Blasticidin   |
|                      | Fenini et al., 2018a| 29287762 | Adult primary keratinocytes| Protein knockout       | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |
|                      | Fenini et al., 2018b| 30096351 | Adult primary keratinocytes| Protein knockout       | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |
|                      | Izmiryan et al., 2018| 30195791 | RDEB primary keratinocytes| Gene correction        | IDLV                   | Lentivirus          | SpCas9        | HDR          | None          |
|                      | Liu et al., 2018   | 30225000 | Adult primary keratinocytes| Protein knockout       | FuGene HD              | Cationic vector     | SpCas9        | NHEJ         | Puromycin     |
|                      | Slikova et al., 2018| 30938974 | Adult primary keratinocytes| CRISPR screen          | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin and blasticidin |
|                      | Herter et al., 2019| 30594489 | Adult primary keratinocytes| Gene activation        | Lipofectamine 2000     | Cationic vector     | dCas9         | n/a          | FACS          |
|                      | Jozic et al., 2019  | 31409528  | Adult primary keratinocytes| Protein knockout       | FuGene HD              | Cationic vector     | SpCas9        | NHEJ         | Puromycin     |
|                      | Grossi et al., 2020| 31502220 | Adult primary keratinocytes| Protein knockout       | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |
| Immortalized keratinocytes| Liu et al., 2016  | 26228041 | HPV16-transformed foreskin primary keratinocytes| Protein knockout    | Lipofectamine 2000     | Cationic vector     | SpCas9        | NHEJ         | Puromycin     |
|                      | Dahnhoff et al., 2017| 28805349 | HaCaT keratinocytes      | Protein knockout       | Lipofectamine 3000     | Cationic vector     | SpCas9        | NHEJ         | FACS          |
|                      | Gao et al., 2017   | 28588028 | HaCaT keratinocytes      | Protein knockout       | pLKO.1-puro            | Lentivirus and adenovirus | SpCas9        | NHEJ         | Puromycin     |
|                      | Sarkar et al., 2018| 30021804 | N/TERT foreskin keratinocytes| Protein knockout      | TransfeX               | Cationic vector     | pSpCas9       | NHEJ         | Geneticin     |
|                      | Swindell et al., 2018| 29434599 | N/TERT foreskin keratinocytes| Protein knockout      | TransfeX               | Cationic vector     | pSpCas9       | NHEJ         | FACS          |
|                      | Trothe et al., 2018| 30252954 | HaCaT keratinocytes and adult primary keratinocytes| Protein knockout    | Ad5-CMV-Cas9 and Ad5-U6-sgRNA | Adenovirus | SpCas9        | NHEJ         | None          |
|                      | Benati et al., 2018| 30122422 | Immortalized JEB adult primary keratinocytes| Protein knockout   | IDLV                   | Lentivirus          | SpCas9        | NHEJ         | None          |
|                      | Chiang et al., 2018| 29263274 | HaCaT keratinocytes       | Protein knockout       | pSicoR-CRISPR-PuroR    | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |
|                      | Sawatsuboashi et al., 2018| 29310493 | HaCaT keratinocytes      | Protein knockin/knockout| Electroproporation     | Plasmid vector     | SpCas9        | NHEJ         | Puromycin     |
|                      | Sun et al., 2018   | 29807809 | HaCaT keratinocytes      | Protein knocknout      | DNAJ4-gRNA-EGFP and Cas9-puro | Lentivirus | SpCas9        | NHEJ         | Puromycin     |
|                      | Zhong et al., 2018  | 30132045 | HaCaT keratinocytes      | Protein knockin       | GenJet                 | Cationic vector    | SpCas9        | HDR          | Geneticin     |
|                      | Baida et al., 2018  | 30410676 | HaCaT keratinocytes      | Protein knockin       | RNAi-Max               | RNP complex        | SpCas9        | NHEJ         | None          |
|                      | Bonafont et al., 2019| 30930113 | Immortalized adult primary keratinocytes| Protein knockout    | Electroproporation     | RNP complex        | SpCas9        | NHEJ         | None          |
|                      | James et al., 2019  | 31391281 | N/TERT foreskin keratinocytes| Protein knockin      | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |
|                      | Hatterschide et al., 2019| 32581101 | Foreskin primary keratinocytes and N/TERT-1 foreskin keratinocytes| Protein knockin      | lentiCRISPR v2 and pXPR_011 | Lentivirus | SpCas9        | NHEJ         | Puromycin and blasticidin |
|                      | Choi et al., 2019  | 31319135 | HaCaT keratinocytes      | Protein knockin       | lentiCRISPR v2          | Lentivirus          | SpCas9        | NHEJ         | Puromycin     |

(continued)
vector carrying a wild-type LAMB3 donor template flanked by homology arms (Benati et al., 2018). These elegant studies illustrate that CRISPR-Cas9 can be utilized for the restoration of protein expression in patient-derived KCs through highly specific approaches, for example, through the incorporation of a donor oligonucleotide by HDR or by the use of dual sgRNA to remove a specific DNA sequence to correct for frameshift mutations. In addition, these studies show that gene-corrected, patient-derived KCs generated are usually of high quality in terms of skin-equivalent generation and suitable for grafting onto immunodeficient mice. In principle, that would make them good candidates for ex vivo gene and protein expression in patient-derived KCs through highly specific approaches, for example, through the incorporation of a donor oligonucleotide by HDR or by the use of dual sgRNA to remove a specific DNA sequence to correct for frameshift mutations. In addition, these studies show that gene-corrected, patient-derived KCs generated are usually of high quality in terms of skin-equivalent generation and suitable for grafting onto immunodeficient mice. In principle, that would make them good candidates for ex vivo gene and

| Cell source | Publication | PMID | Cell Types (All Human) | Research Goal | Method of Introduction | Carrier | Cas9 Version | Repair | Selection |
|------------|-------------|------|------------------------|---------------|-----------------------|---------|--------------|--------|-----------|
| Stump et al., 2020 | 30972602 | HaCaT keratinocytes | Protein knockout | lentCRISPR v2 | Lentivirus | SpCas9 | NHEJ | Puromycin |
| Muraguchi et al., 2019 | 31122679 | HaCaT keratinocytes | Protein knockout | TransIT-LT1 | Cationic vector | SpCas9 | NHEJ | FACS |
| Walter et al., 2019 | 31178865 | HaCaT keratinocytes | Protein knockout | Lipofectamine 2000 | Cationic vector | SpCas9 | NHEJ | FACS |
| Hatterschide et al., 2020 | 32581101 | foreskin primary keratinocytes and N/TERT-1 foreskin keratinocytes | Protein knockout | lentCRISPR v2 and pXPR_011 | Lentivirus | SpCas9 | NHEJ | Puromycin and blasticidin |
| Casares et al., 2020 | 31518892 | HaCaT keratinocytes | Protein knockout | lentCRISPR v2 | Lentivirus | SpCas9 | NHEJ | Puromycin |
| Gálvez et al., 2020 | 32637457 | Immortalized primary adult keratinocytes | Protein knockout | Electroporation | RNP complex | SpCas9 | NHEJ | No |
| Enjalbert et al., 2020 | 32544098 | N/TERT foreskin keratinocytes | Protein knockout | FuGene 6 and Hiperfect | Cationic vector | SpCas9 | NHEJ | FACS |
| Kocher et al., 2020 | 32142798 | Immortalized adult primary keratinocytes and RDEB primary keratinocytes | Gene activation and protein knockout | Electroporation | RNP complex | SpCas9 | NHEJ | None |
| Dabelsteen et al., 2020 | 32710848 | N/TERT foreskin keratinocytes | Protein knockout | lentCRISPR v2 | Lentivirus | SpCas9 | NHEJ | Puromycin and blasticidin |
| Imahorn et al., 2020 | 32917957 | Immortalized epidermolytic ichthyosis keratinocytes | Protein knockout | Xfect | Cationic vector | SpCas9 | NHEJ | FACS |
| James et al., 2020 | 32938703 | N/TERT foreskin keratinocytes | Protein knockout | Calcium phosphate transfection | Plasmid vector | SpCas9 | NHEJ | Puromycin |
| Sobiak and Letnack, 2020 | 33297464 | HaCaT keratinocytes | Protein knockout | Lipofectamine 3000 | Cationic vector | SpCas9 | NHEJ | FACS |
| Bonafont et al., 2021 | 33609734 | Immortalized adult primary keratinocytes | Protein knockout | Lipofectamine 3000 | Cationic vector | SpCas9 | NHEJ | FACS |
| Abboodl et al., 2021 | 33321328 | HPV16-transformed foreskin primary keratinocytes | Protein knockout | Lipofectamine 3000 | Cationic vector | SpCas9 | NHEJ | FACS |
| Wanuske et al., 2021 | 33354837 | HaCaT keratinocytes | Protein knockout | Lipofectamine 3000 | Cationic vector | SpCas9 | NHEJ | FACS |
| O’Keeffe and Ahern, 2021 | 34363036 | Immortalized primary adult keratinocytes | Protein knockout | Lipofectamine 3000 | RNP complex | SpCas9 | NHEJ | FACS |
| Ehrard et al., 2021 | n/a | N/TERT foreskin keratinocytes | Protein knockout | Electroporation | RNP complex | SpCas9 | NHEJ | None |
| Kocher et al., 2021 | 34458008 | Immortalized RDEB primary keratinocytes and fibroblasts | Gene correction | Electroporation | RNP complex | SpCas9 | NHEJ | HDR |

iPSC

| Sebastian et al., 2014 | 25429056 | Induced pluripotent stem cell–derived keratinocytes | Gene correction | Electroporation | Plasmid vector | SpCas9 | HDR | Geneticin and ganciclovir |
|----------------------|-----------|-------------------------------------------------|-----------------|-----------------|-----------|--------|------|-------------------|
| Webber et al., 2016 | 28250968 | Induced pluripotent stem cells | Gene correction | Electroporation | Plasmid vector | hCas9 | HDR | Puromycin |
| Shinkuma et al., 2016 | 27143720 | Induced pluripotent stem cells | Gene correction | Electroporation | Plasmid vector | SpCas9 | NHEJ | FACS |
| Jackow et al., 2019 | 31818947 | Induced pluripotent stem cells | Gene correction | Electroporation | RNP complex | SpCas9 | HDR | FACS |
| Itok et al., 2020 | 32376125 | Induced pluripotent stem cells | Gene correction | Electroporation | RNP complex | SpCas9 | HDR | Puromycin |

Abbreviations: Cas9, Cas9 nickase; hCas9, human codon optimized Cas9; HDR, homology-directed repair; IDLV, integrase-deficient lentiviral particles; iPSC, induced pluripotent stem cell; JEB, junctional epidermolysis bullosa; NHEJ, nonhomologous end joining; PMID, PubMed identifier; RDEB, recessive dystrophic epidermolysis bullosa; RNP, Ribonucleoprotein; SpCas9, Streptococcus pyogenes Cas9.
Human-immortalized KCs as alternative cell source

Human primary KCs in epidermal equivalent culture models represent the in vivo epidermis quite well. However, human donor skin is not always available, primary KCs isolation is time consuming, and primary KCs have a short in vitro lifespan. This conflicts with the extensive culture protocols and serial passaging that are necessary for genome-editing strategies. Therefore, many researchers make use of immortalized KCs in studies that are usually aimed at (i) gene and protein function by full knock out (Abboodi et al., 2021), (ii) the biological consequence of a knock out on cell function or during therapeutic conditions (Abboodi et al., 2021; Casares et al., 2020; Choi et al., 2019; Dahloff et al., 2017; Hatterschide et al., 2019, 2020; James et al., 2019; Swindell et al., 2018; Trothe et al., 2018), (iii) validation of therapeutic target (Abboodi et al., 2021; Liu et al., 2016), or (iv) generating disease model cell lines (Enjalbert et al., 2020; Sarkar et al., 2018).

Immortalized KCs, such as the spontaneously immortalized HaCaT KCs, the N/TERT-1, and N/TERT-2G KCs, or the less used HPV16-induced immortalized KCs do not have these limitations and thus provide an alternative unlimited cell source (Boelsma et al., 1999; Smits et al., 2017). Therefore, most studies using CRISPR-Cas9 in human KCs have been performed in either of the immortalized KC cell lines (Figure 1c and Table 1). Although multiple cell sources are available, they are not equally comparable with primary KCs and are not necessarily similarly suited for genomic engineering procedures. The HaCaT KCs are frequently used as a model for KCs in vitro as both monolayer and human skin equivalents (Schoop et al., 1999). However, epidermal stratification is abnormal, aberrant epidermal differentiation protein expression is observed, and a stratum corneum is often lacking. Another drawback is that HaCaT cells show aneuploidy. Taken together, this makes HaCaT KCs less suitable for genome editing and studying epidermal differentiation. The N/TERT-1 and N/TERT-2G KC cell lines were immortalized by the introduction of the hTERT gene and by spontaneous loss of the pRB/p16INK4A cell cycle control mechanism (Dickson et al., 2000). The N/TERT KC cell lines are (largely) diploid (N/TERT-1: 47, XY + 20, N/TERT-2G: 46, XY) and show similar differentiation characteristics to those of human primary KCs (Smits et al., 2017), which renders them more suitable for genomic intervention tools such as CRISPR-Cas9. Immortalized KCs are well-suited for fundamental studies into protein function, possible therapeutic targets, or disease modeling studies but are not applicable for in vivo treatment purposes. In contrast, KCs derived from induced pluripotent stem cells (iPSCs) would be more suitable with regard to regenerative medicine.

**KCs derived from CRISPR-Cas9–edited iPSCs**

Human pluripotent stem cells (hPSCs) and iPSCs offer great promise in regenerative medicine both for disease modeling and for tissue regeneration because they can proliferate indefinitely and can be differentiated to almost any cell type in the human body (Yamanaka and Blau, 2010). Owing to their unlimited proliferation capacity (Takahashi and Yamanaka, 2006), hPSCs and iPSCs have an apparent advantage over other somatic cells or even adult stem cells in genomic-editing studies using CRISPR-Cas9, especially when clonal selection is necessary. Numerous studies reported such strategies to obtain genome-edited cells from tissues that are normally not easily retrievable (Hendriks et al., 2020; Hockemeyer and Jaenisch, 2016). In dermatological research, most studies are on iPSCs derived from patients with EB. For example, iPSCs were generated from fibroblasts derived from a patient with dominant dystrophic EB carrying a heterozygous COL7A1 mutation. Subsequently, plasmids carrying Cas9 and mutation-site–specific sgRNAs were transfected into these iPSCs before positive selection by flow cytometry. The mutation-site–specific sgRNAs ensured that the correction of the genetic sequence occurred only on the mutated allele but not on the wild type (Shinkuma et al., 2016). Others show the correction of the COL7A1 gene in RDEB iPSCs by adeno-associated genome editing (Sebastiano et al., 2014) through the introduction of three plasmids encoding Cas9, gRNA, and donor-repair template (Webber et al., 2016) or through electroporation with sgRNA/Cas9 RNP complexes (Jacków et al., 2019). Induced KCs (iKCs) derived from gene-corrected iPSCs were grafted onto immunodeficient mice, and 2 months after grafting, a normal expression of COL7A1 is shown (Jacków et al., 2019). Although the generation of genome-edited iPSCs is relatively easy, differentiation from iPSC toward iKC, especially for resembling primary KCs, is less straightforward (Kogut et al., 2014; Sah et al., 2021; Soares and Zhou, 2020). In addition, iPSC-derived KCs are often immature, compared with primary KCs derived from the skin, which is a common feature of many iPSC-derived cells (Friedman et al., 2018; Soares et al., 2019). Although the traditional air–liquid interface cultures are challenging in iPSC-derived cells, other options are available. Groundbreaking work has shown a human iPSC–based organoid culture system in which skin appendages (e.g., hair follicles and sebaceous glands) are present (Lee et al., 2020). Organoids as such would be suitable to study aspects that are impossible to study in traditional skin equivalents, such as (early) developmental processes. Empowered by CRISPR-Cas9 genomic engineering and analysis techniques at single-cell resolution, these organoid cultures are highly promising options for future research into the skin.

**Future perspective for the use of CRISPR-Cas9 in experimental dermatology**

To date, no clinical experiments have been performed or are registered using CRISPR-Cas9 in primary KCs to treat skin disorders, although CRISPR-Cas9–based in vivo experiments have been reported in murine models. For example, mouse tail skin was successfully electroporated with DNA plasmids (encoding gRNAs and Cas9) and RNP complexes of synthetic Cas9 and in vitro transcribed sgRNAs (Wu et al., 2017). In 2017, Hirsch et al. (2017) experimentally treated a patient with JEB with a homozygous mutation in the LAMB3 gene, which owing to the blistering and infections had lost over
80% of his epidermis. Although this is a great example of gene therapy, it was not CRISPR-Cas9 based but was through ex vivo gene replacement by viral transduction of LAMB3 cDNA.

**Conclusion and future directions**

Before in vivo CRISPR-Cas9 can be considered in clinical practice, many improvements on CRISPR-Cas9 machinery, that is, component stability, in vivo delivery, editing accuracy, non-specific and unintended off-target effects, and control of cellular repair mechanisms are necessary (Li et al., 2018). In addition, Cas9 has been reported to elicit immune responses in mice (Chew et al., 2016; Wang et al., 2015) and humans (Simhadri et al., 2018; Wagner et al., 2019), posing a challenge for CRISPR-Cas9–based genomic engineering (Crudele and Chamberlain, 2018). Nevertheless, the impact of this immunological challenge needs to be studied in immuno-competent (humanized) animal models to assess the potential strategies to minimize the impact of anti-Cas9 antibodies and T cells. Until then, realistic and important goals for CRISPR-Cas9 implementation are to further develop in vitro human disease models to benefit preclinical research, therapeutic target discovery, and drug screening.

Monogenetic disorders of the epidermis can be modeled, and the effects of therapies can be studied extensively without the need for primary KCs, patient biopsies, or animal models. Besides KCs, other skin cell types—such as fibroblasts—are of interest too. Research on dystrophic EB pathogenesis indicated that both KCs and fibroblasts are responsible for the expression of COL7 (COL7A1), where the contribution of fibroblasts overrules that of KCs (Goto et al., 2006). Fibroblasts are considered a more robust and easier to culture type of cells than KCs, which renders them suitable for prolonged culturing and genomic engineering (Chen and Woodley, 2006) and a potential target cell type for gene and cell therapy in dystrophic EB (Izmiryan et al., 2018; Jackow et al., 2021; Kocher et al., 2019; takashima et al., 2020). As this field of research expands, lessons can be taken from experimental approaches that were successful in epidermal KCs and applied to dermal fibroblasts and vice versa.

Non-specific endonuclease activity can result in off-target unintended genomic alterations. Ever since the first application of CRISPR-Cas9 in mammalian cells, progress has been made to mitigate the incidence of off-target DNA cleavage by non-specific endonuclease activity resulting in off-target unintended genomic alterations, as reviewed recently (Naeem et al., 2020). These strategies range from but are not limited to modification of gRNA, modification of Cas9 (e.g., deactivat- ed Cas9 [dCas9], Cas9 nickase [Cas9n], high-fidelity Cas9), fine-tuning delivery methodology, application of base editors (dCas9 combined with deaminase and gRNA), and application of prime editing (Cas9n combined with reverse transcriptase). Therefore, besides selecting editing strategies on the basis of maximizing editing efficiencies and cell viability, different options are now available to minimize off-target risks. These should be taken into consideration depending on which safety measures are applicable for the purpose of genomic engineering.

Besides investing in methodological improvements using currently available (immortalized) KCs (e.g., target DNA site selection, sgRNA design and delivery methods, off-target DNA cleavage, NHEJ and HDR incidence and efficiency, and Cas9 activity), efforts should also be directed to the generation of new skin cell sources to increase experimental diversity and account for population, sex, and age differences. Having CRISPR-Cas9 technology at hand, more complex, multicellular, immunocompetent, and vascularized organotypic skin models with higher throughput can be developed. These innovations will further propel the implementation and acceptance of organotypic human skin models as excellent alternatives or superior experimental models to the traditional use of animals in biomedical research.

**ORCIDs**

Jos PF, Smits: http://orcid.org/0000-0003-9715-8624
Luca D. Meesters: http://orcid.org/0000-0002-2554-7761
Berber G.W. Maste: http://orcid.org/0000-0002-3932-8738
Huang Zhou: http://orcid.org/0000-0002-2434-3986
Patrick EJ.M. Zeeuwen: http://orcid.org/0000-0002-6878-2438
Ellen H. van den Bogaard: http://orcid.org/0000-0003-4846-0287

**AUTHOR CONTRIBUTIONS**

Conceptualization: JPHS, LDM, BGWM, EHVD; Funding Acquisition: EHVD, PLJMZ; Project Administration: JPHS, EHVD; Resources: EHVD; Supervision: EHVD; Visualization: JPHS, LDM; Writing - Original Draft Preparation: JPHS, BGWM, HZ; Writing - Review and Editing: JPHS, LDM, HZ, PLJMZ, EHVD

**ACKNOWLEDGMENTS**

This work was supported by an LEO Foundation grant (LF18068 to EHVD and PLJMZ) and PAST4FUTURE grant LSHM20043-HSGF (to EHVD and HLJMZ).

**CONFLICT OF INTEREST**

The authors state no conflicts of interest.

**REFERENCES**

Abboodi F, Buckbaths P, Almatare D, Liu C, Hosseinipour M, Banister CE, et al. HPV-inactive cell populations arise from HPV16-transformed human keratinocytes after p53 knockout. Virology 2021;534:9–16.

Bald I, Bhalla P, Yemelyanov A, Stechschulte LA, Shou W, Readhead B, et al. Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy. Oncotarget 2018;9:34772–83.

Benati D, Miselli F, Ciccarella F, Patrizi C, Carretero M, Baldassarri S, et al. CRISPR/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther 2018;26: 2592–603.

Boelma E, Verhoeven MC, Ponec M. Reconstruction of a human skin equivalent using a spontaneously transformed keratinocyte cell line (HaCaT). J Invest Dermatol 1999;112:489–98.

Bonafont J, Mencía A, Chacón-Solano E, Srifa W, Vaidyanathan S, Romano R, et al. Correction of Recessive Dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Mol Ther 2021;29: 2008–18.

Bonafont J, Mencía Á, García M, Torres R, Rodríguez S, Carretero M, et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR/Cas9-mediated gene editing. Mol Ther 2019;27: 986–98.

Casares L, García V, Garrido-Rodríguez M, Millán E, Collado JA, García-Martín A, et al. Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol 2020;28:101321.

Chen F, Pruett-Miller SM, Huang Y, Gjoka M, Duda K, Taunton J, et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods 2011;8:753–5.

Chen M, Woodley DT. Fibroblasts as target cells for DEB gene therapy. J Invest Dermatol 2006;126:708–11.
Grossi S, Feni G, Hennig P, Di Filippo M, Beer HD. Generation of knockout human primary keratinocytes by CRISPR-Cas9. Methods Mol Biol 2020;2109:125–45.

Hainzl S, Peking P, Kocher T, Murauer EM, Larcher F, Del Rio M, et al. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther 2017;25:2573–4.

Hatterschide J, Bohidar AE, Grace M, Nulton TJ, Kim HW, Windle B, et al. PTPN14 degradation by high-risk human papillomavirus E7 limits keratinoocyte differentiation and contributes to HPV-mediated oncogenesis. Proc Natl Acad Sci USA 2019;116:7033–42.

Hatterschide J, Brantly AC, Grace M, Munger K, White EA. A conserved amino acid in the C terminus of human papillomavirus E7 mediates binding to PTPN14 and repression of epithelial differentiation. J Virol 2020;94.

Hefferin ML, Tomkinson AE. Mechanism of DNA double-strand break repair by non-homologous end joining. DNA Repair 2005;4:639–48.

Hendriks D, Clevers H, Artegiani B. CRISPR-Cas tools and their application in genetic engineering of human stem cells and organoids. Cell Stem Cell 2020;27:705–31.

Herter EK, Li D, Toma MA, Vij M, Li X, Visscher D, et al. WAKMAR2, a long noncoding RNA downregulated in human chronic wounds, modulates keratinocyte motility and production of inflammatory chemokines. J Invest Dermatol 2019;139:1373–84.

Hirsch T, Rothoefl T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017;551:327–32.

Hockemeyer D, Jaenisch R. Induced pluripotent stem cells meet genome editing. Cell Stem Cell 2016;18:573–86.

Imahon M, Aushov M, Herms S, Hoffmann P, Cichon S, Reichelt J, et al. Gene expression is stable in a complete CIB1 knockout keratinocyte model. Sci Rep 2020;10:14952.

Itoh M, Kawagoe S, Tamai K, Nakagawa H, Asahina A, Okano HJ. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system. J Dermatol Sci 2020;98:163–72.

Izmirlian A, Ganier C, Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR/Cas9 and homology-directed repair. Mol Ther Nucleic Acids 2018;12:554–67.

Jacków J, Guo Z, Hansen C, Abaci HE, Doucet YS, Shin JU, et al. CRISPR-Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPSC. Proc Natl Acad Sci USA 2019.

Jacków J, Titleux M, Portier S, Charbonnier S, Ganier C, Gaucher S, et al. Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a self-inactivating COL7A1 retroviral vector. J Invest Dermatol 2016;136:1346–54.

James CD, Das D, Morgan EL, Otoa R, Macdonald A, Morgan IM. Werner syndrome protein (WRN) regulates cell proliferation and the human papillomavirus type II CRISPR immunity systems. RNA Biol 2013;10:726–39.

Jin Y, Kim HW, Windle B, et al. CRISPR-Cas9-mediated COL7A1 reframing for dystrophic epidermolysis bullosa. J Invest Dermatol 2020;140:1985–93.e5.
Kocher T, Peking P, Klaussegger A, Murauer EM, Hofbauer JP, Wally V, et al. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR-Cas9 nickases. Mol Ther 2017;25:2585–98.

Kogut I, Roop DR, Bilusova G. Differentiation of human induced pluripotent stem cells into a keratinocyte lineage. Methods Mol Biol 2014;1195:1–12.

Lee J, Rabhani CC, Gao H, Steinhart MR, Woodruff BM, Plium ZE, et al. Hair-bearing human skin generated entirely from pluripotent stem cells. Nature 2020;582:399–404.

Li L, Hu S, Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials 2018;171:207–18.

Liang F, Han M, Romanienko PJ, Jasin M. Expression of a site-specific endonuclease stimulates homology-directed repair with oligodeoxynucleotides: wanted and unwanted target locus apoptosis by targeting NRAS. R Soc Open Sci 2018;5:172376.

Liu YC, Cai ZM, Zhang XJ. Reprogrammed CRISPR-Cas9 targeting the conserved regions of HPV6/11 E7 genes inhibits proliferation and induces apoptosis in E7-transformed keratinocytes. Asian J Androl 2016;18:475–9.

Makarova KS, Haft DH, Barrangou R, Brouns SJ, Charpentier E, Horvath P, et al. Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 2011;9:467–77.

Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science 2013;339:823–6.

Muraguchi T, Namba D, Nishimura EK, Tashiro T. IGF-1R deficiency in human keratinocytes disrupts epidermal homeostasis and stem cell maintenance. J Dermatol Sci 2019;94:298–305.

Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the off-target effects in CRISPR-cas-mediated genome editing. Cells 2020;9:1608.

Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010;17:295–304.

Nöske K, Stark HJ, Nevaril L, Berning M, Langbein L, Goyal A, et al. Mitotic diversity in homeostatic human interfollicular epidermis. Int J Mol Sci 2016;17:167.

O’Keeffe Abern J, Lara-Sáez I, Zhou D, Murillas R, Bonafont J, Mencía Á, et al. Non-viral delivery of CRISPR-Cas9 complexes for targeted gene editing via a polymer delivery system[e-pub ahead of print]. Gene Ther 2021. https://doi.org/10.1038/s41434-021-00282-6 (accessed November 12, 2021).

Radecke S, Radecke F, Cathomen T, Schwarz K. Zinc-finger nuclease-induced apoptosis of versatile non-homologous end-joining-based knock-in module for genome editing. Nat Methods 2018;15:467–77.

Rouet P, Smith F, Jason M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Nat Acad Sci USA 1994;91:6064–8.

Ryynänen M, Knowlton RG, Parente MG, Chung LC, Chu ML, Uitto J. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa. Sci Transl Med 2014;6:244ra163.

Shah SA, Erdmann S, Mojica FJ, Garrett RA. Protopsacer recognition motifs: mixed identities and functional diversity. RNA Biol 2013;10:891–9.

Shi H, Smits JPH, van den Bogaard EH, Brewer MG. Research techniques made simple: delivery of the CRISPR/Cas9 components into epidermal cells. J Invest Dermatol 2021;141:1375–81.e1.

Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc Natl Acad Sci USA 2016;113:5676–81.

Simhadi VL, McGill J, McMahon S, Wang J, Jiang H, Sauna ZE. Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population. Mol Ther Methods Clin Dev 2018;10:105–12.

Slivka PF, Hsieh CL, Lipovsky A, Pratt SD, Locklear J, Namovic MT, et al. Small molecule and pooled CRISPR screens investigating IL17 signaling identify BRD2 as a novel contributor to keratinocyte inflammatory responses. ACS Chem Biol 2019;14:857–72.

Smith FJ, Irvine AD, Terron-Kwiatkowski A, Sandiliands A, Campbell LE, Zhao Y, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006;38:337–42.

Smits JPH, Niehues H, Rikken G, van Vlijmen-Willems IMJ, van de Zande GWMF, Zeeuwen PLJM, et al. Immortalized N/TERT keratinocytes as an alternative cell source in 3D human epithelial models. Sci Rep 2017;7:11838.

Soares E, Xu Q, Li Q, Qu J, Zheng Y, Raenew HHM, et al. Single-cell RNA-seq identifies a reversible mesodermal activation in abnormally specified epithelia of p63 EEC syndrome. Proc Natl Acad Sci USA 2019;116:17361–70.

Soares E, Zhou H. Pluripotent stem cell differentiation toward functional basal stratified epithelial cells. Methods Mol Biol 2020.

Sobiak B, Lesniak W. Effect of UV399H histone methyltransferase knockout on expression of differentiation-associated genes in HaCaT keratinocytes. Cells 2020;9.

Stephen SL, Montini E, Sivanandam VG, Al-Dhalimy M, Kestler HA, Finegold M, et al. Chromosomal integration of adenoviral vector DNA in vivo. J Virol 2010;84:9987–94.

Stump CL, Feehan RP, Jordan T, Shantz LM, Nowotarski SL. Knocking down raptor in human keratinocytes affects ornithine decarboxylase in a post-transcriptional Manner following ultraviolet B exposure. Amino Acids 2020;52:141–9.

Sun YZ, Ren Y, Zhang YJ, Han Y, Yang Y, Gao YL, et al. DNA/A4 deficiency enhances NF-kappa B-related growth arrest induced by hyperthermia in human keratinocytes. J Dermatol Sci 2018;91:256–67.

Swindell WR, Beamer MA, Sarkar MK, Loftus S, Fullmer J, Xing X, et al. RNA-seq analysis of IL-1β and IL-36 responses in epidermal keratinocytes identifies a shared MyD88-dependent gene signature. Front Immunol 2018:9:60.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663–76.

Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, et al. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR/Cas9. J Invest Dermatol 2019;139:1711–21.e4.

Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, et al. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. EMBO J 1998;17:5497–508.

Thyssen JP, Godoy-Gijon E, Elias PM. Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 2013;168:1155–66.

Trothe J, Ritzmann D, Lang V, Scholz P, Úl Puml, Kaufmann R, et al. Hypotonic stress response of human keratinocytes involves LRRC8A as component of volume-regulated anion channels. Exp Dermatol 2018;27:1352–60.

Wagner DL, Amini L, Wendering DJ, Burkhardt LM, Akýüz L, Reineke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med 2019;25:242–8.
Walter E, Vielmuth F, Wanuske MT, Seifert M, Pollmann R, Eming R, et al. Role of Dsg1- and Dsg3-mediated signaling in pemphigus autoantibody-induced loss of keratinocyte cohesion. Front Immunol 2019;10:1128.

Wang D, Mou H, Li S, Li Y, Hough S, Tran K, et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum Gene Ther 2015;26:432–42.

Wanuske MT, Brantschen D, Schinner C, Stüde C, Walter E, Hiermaier M, et al. Clustering of desmosomal cadherins by desmoplakin is essential for cell-cell adhesion. Acta Physiol (Oxf) 2021;231:e13609.

Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, et al. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med 2016;1.

Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci U S A 2017;114:1660–5.

Yamanaka S, Blau HM. Nuclear reprogramming to a pluripotent state by three approaches. Nature 2010;465:704–12.

Yue J, Gou X, Li Y, Wicksteed B, Wu X. Engineered epidermal progenitor cells can correct diet-induced obesity and diabetes. Cell Stem Cell 2017;21:256–63.e4.

Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adenovirus-associated virus vectors. J Virol 2002;76:4580–90.

Zaiss AK, Muruve DA. Immunity to adenovirus-associated virus vectors in animals and humans: a continued challenge. Gene Ther 2008;15:808–16.

Zhong G, Li H, Bai J, Pang S, He C, Du X, et al. Advancing the predictivity of skin sensitization by applying a novel HMOX1 reporter system. Arch Toxicol 2018;92:3103–15.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/